1. Home
  2. LCTX vs DSP Comparison

LCTX vs DSP Comparison

Compare LCTX & DSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Logo Viant Technology Inc.

DSP

Viant Technology Inc.

HOLD

Current Price

$11.93

Market Cap

198.1M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCTX
DSP
Founded
1990
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
407.7M
198.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
LCTX
DSP
Price
$1.65
$11.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
8
Target Price
$4.25
$18.50
AVG Volume (30 Days)
1.3M
229.2K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
29.49
EPS
N/A
0.10
Revenue
$10,816,000.00
$324,131,000.00
Revenue This Year
$6.32
$17.79
Revenue Next Year
$124.49
$17.72
P/E Ratio
N/A
$121.66
Revenue Growth
24.05
22.97
52 Week Low
$0.37
$8.11
52 Week High
$2.09
$26.33

Technical Indicators

Market Signals
Indicator
LCTX
DSP
Relative Strength Index (RSI) 43.84 63.23
Support Level $1.63 $11.54
Resistance Level $1.77 $12.15
Average True Range (ATR) 0.08 0.49
MACD -0.01 -0.05
Stochastic Oscillator 16.67 60.47

Price Performance

Historical Comparison
LCTX
DSP

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About DSP Viant Technology Inc.

Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.

Share on Social Networks: